GlassScriptPhysician profile
Marybeth Dixon
NPI 1992812903
$1,808.37
in general payments reported to CMS, 2019-2025
29 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $153 · 2021: $210 · 2022: $349 · 2023: $311 · 2024: $294 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $838.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $303.12 | 2019-2025 | Lo Loestrin Fe |
| Bayer Healthcare Pharmaceuticals INC. | $179.17 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $178.40 | 2023-2025 | Myfembree |
| Pfizer INC. | $139.78 | 2019-2025 | |
| Astellas Pharma US INC | $134.17 | 2023-2025 | Veozah |
| Daiichi Sankyo INC. | $124.30 | 2019-2025 | Injectafer |
| Myovant Sciences INC. | $76.94 | 2021-2022 | |
| Hologic Sales and Service, LLC | $73.73 | 2019-2024 | Aptima, Novasure, Myosure Tissue Removal Device |
| Organon LLC | $72.84 | 2022-2024 | Nexplanon |
| Exeltis, USA INC. | $55.33 | 2022-2025 | Slynd |
| Coopersurgical, INC. | $48.41 | 2019-2021 | |
| Millicent US INC | $45.47 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Merck Sharp & Dohme LLC | $42.40 | 2019 | |
| Agile Therapeutics, INC. | $36.92 | 2021-2024 | Twirla |
| Mayne Pharma Commercial LLC | $35.10 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $30.14 | 2019 | |
| Novartis Pharmaceuticals Corporation | $30.12 | 2023 | |
| Amag Pharmaceuticals, INC. | $27.30 | 2019 | |
| Aspira Women'S Health INC | $25.64 | 2024 | Ova1 |
| Therapeuticsmd, INC. | $23.83 | 2021 | |
| Evofem Biosciences, INC. | $19.52 | 2021 | |
| Scynexis, INC. | $18.59 | 2022 | |
| Minerva Surgical, INC | $13.46 | 2022 | |
| Lupin INC. | $13.33 | 2019 | |
| Avion Pharmaceuticals | $13.20 | 2022 | |
| Olympus America INC. | $12.30 | 2020 | |
| Mycovia Pharmaceuticals, INC. | $12.02 | 2022 | |
| Meditrina | $11.61 | 2024 | |
| Smith+Nephew, INC. | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marybeth Dixon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.